Overview
To assess the early bactericidal activity of Azithromycin 250mg by mouth daily over the first 14 days of treatment for Mycobacterium avium complex (MAC) lung disease.
Description
This research is being done to better understand several important aspects of treatment of Mycobacterium avium complex (MAC) lung infections using an early bactericidal activity (EBA) study design. MAC is an environmental bacteria that can cause chronic lung infection. Early bactericidal activity is the amount of bacterial killing that occurs during the first few weeks of antibiotic treatment. By collecting information about the EBA of azithromycin for MAC, the investigators will quantify the efficacy of azithromycin against pulmonary MAC.
Eligibility
Inclusion Criteria:
- Age ≥18 years
- Isolation of M. avium intracellulare complex from a respiratory specimen in the preceding 6 months
- Fulfill American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) criteria for MAC lung disease
- Intention by the treating clinician to treat for MAC lung disease.
- Ability to produce a sputum sample of at least 10mL in a 16 hour period
- Signed informed consent by the subject
Exclusion Criteria:
- Prior treatment for pulmonary MAC within the past 6 months
- Pregnancy
- HIV with a cluster of differentiation 4 (CD4) <350
- History of solid organ or hematologic transplant
- Contraindication to azithromycin
- Has any other condition that, in the opinion of the PI, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
